Design, Conduct, and Analysis of Clinical Trials in Disease Due to Methicillin-Resistant Staphylococcus Aureus
Download Your Copy
We respect your privacy, by submitting this form you agree to having your details passed onto the sponsor who may promote similar products and services related to your area of interest. For further information on how we process and monitor your personal data click here.
Given the changing epidemiology of disease due to Staphylococcus aureus (SA), including the emergence of drug-resistant organisms such as methicillin-resistant SA, investigators may wish to evaluatethe effects of antimicrobials in disease due to SA as well as in disease due to other organisms in the same trial. Here JH Powers and TR Fleming discuss issues that investigators should address in trial design, conduct, and analysisto evaluate overall effects or effects within subgroups according tocausative organisms.
To continue reading this story get free access
Please note: That all fields marked with an asterisk (*) are required.